Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features

Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...

Cardiomyopathy IV: Restrictive Cardiomyopathy

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...

Chronic Obstructive Pulmonary Disease II: Emphysema

Chronic Obstructive Pulmonary Disease II: Emphysema

Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation

Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...

Chronic Obstructive Pulmonary Disease-I: Introduction

Chronic Obstructive Pulmonary Disease-I: Introduction

Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Aberrant and Ectopic Cell Populations in Restrictive Allograft Syndrome after Lung Transplantation.

The European respiratory journal·2026

Same author

Alveolar niche disruption and aberrant epithelial reprogramming are early hallmarks of idiopathic pulmonary fibrosis.

bioRxiv : the preprint server for biology·2026

Same author

A Transcriptomic Atlas of Chronic Lung Allograft Dysfunction.

The European respiratory journal·2026

Same author

Blood vessels as primary site of rejection in murine lung transplantation.

Transplant international : official journal of the European Society for Organ Transplantation·2026

Same author

Correction: Prisciandaro et al. Anatomical Versus Non-Anatomical Pulmonary Metastasectomy: European Multicentre Analysis. <i>Cancers</i> 2026, <i>18</i>, 1037.

Cancers·2026

Same author

Three-dimensional micro-CT analysis of vascular remodeling and vascular pruning in pulmonary arterial hypertension.

The European respiratory journal·2026

Search research articles

Related Experiment Video

Updated: Apr 18, 2026

Development of Obliterative Bronchiolitis in a Murine Model of Orthotopic Lung Transplantation

Development of Obliterative Bronchiolitis in a Murine Model of Orthotopic Lung Transplantation

Published on: July 10, 2012

Restrictive chronic lung allograft dysfunction: Where are we now?

Stijn E Verleden¹, David Ruttens¹, Elly Vandermeulen¹

¹Department of Clinical and Experimental Medicine, Laboratory of Pneumology, Lung Transplant Unit, Katholieke Universiteit Leuven and University Hospitals, Leuven, Belgium.

The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation

|January 12, 2015

Summary

A restrictive phenotype of chronic lung allograft dysfunction (rCLAD) is a serious complication after lung transplantation. This condition has a poor prognosis, necessitating further research into effective therapies.

Keywords:

bronchiolitis obliterans syndrome chronic lung allograft dysfunction lung transplantation restriction restrictive allograft syndrome

More Related Videos

Author Spotlight: Investigating the Key Factors of Obliterative Bronchiolitis After Lung Transplantation

Author Spotlight: Investigating the Key Factors of Obliterative Bronchiolitis After Lung Transplantation

Published on: November 10, 2023

Lung Rapid Recovery Procurement Combined with Abdominal Normothermic Regional Perfusion in Controlled Donation after Circulatory Death

Lung Rapid Recovery Procurement Combined with Abdominal Normothermic Regional Perfusion in Controlled Donation after Circulatory Death

Published on: August 15, 2022

Related Experiment Videos

Last Updated: Apr 18, 2026

Development of Obliterative Bronchiolitis in a Murine Model of Orthotopic Lung Transplantation

Development of Obliterative Bronchiolitis in a Murine Model of Orthotopic Lung Transplantation

Published on: July 10, 2012

Author Spotlight: Investigating the Key Factors of Obliterative Bronchiolitis After Lung Transplantation

Author Spotlight: Investigating the Key Factors of Obliterative Bronchiolitis After Lung Transplantation

Published on: November 10, 2023

Lung Rapid Recovery Procurement Combined with Abdominal Normothermic Regional Perfusion in Controlled Donation after Circulatory Death

Lung Rapid Recovery Procurement Combined with Abdominal Normothermic Regional Perfusion in Controlled Donation after Circulatory Death

Published on: August 15, 2022

Area of Science:

Pulmonology
Transplantation Medicine
Radiology

Background:

Chronic lung allograft dysfunction (CLAD) is a common complication post-lung transplantation.
Bronchiolitis obliterans syndrome (BOS) is the most recognized form of CLAD.
A distinct restrictive phenotype, rCLAD, affects 30% of CLAD patients and has a poorer prognosis.

Discussion:

rCLAD diagnosis involves restrictive pulmonary function (FEV1, FVC, TLC decline), imaging findings (infiltrates, thickening), and histopathology (fibroelastosis, obliterative bronchiolitis).
Prognosis for rCLAD is significantly poorer than bronchiolitis obliterans syndrome (BOS), with median survival of 6-18 months versus 3-5 years.
Understanding risk factors and mechanisms is crucial for managing rCLAD.

Key Insights:

rCLAD is characterized by a distinct pattern of lung function decline, imaging abnormalities, and histopathological findings.
The survival rate for rCLAD is substantially lower than for BOS.
Current knowledge gaps exist regarding rCLAD, emphasizing the need for further investigation.

Outlook:

Further research is essential to elucidate the underlying mechanisms and risk factors of rCLAD.
Development of effective therapeutic strategies for rCLAD is urgently required.
Addressing knowledge gaps will improve understanding and management of this complication.